0RNK Stock Chart & Stats
€4.80
€0.03(1.17%)
At close: 4:00 PM EST
€4.80
€0.03(1.17%)
Day’s Range― - ―
52-Week Range€2.85 - €6.19
Previous CloseN/A
Volume2.44K
Average Volume (3M)16.48K
Market Cap
€897.69M
Enterprise Value€722.43
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume29,766
30 Day Avg. Volume16,477
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.68Price Target Upside80.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€5.70M
Bulls Say, Bears Say
Bulls Say
Well-powered Phase III (NATiV3) Enrollment CompletedCompleting a >90%‑powered, >1,000‑patient Phase III trial materially reduces statistical uncertainty versus smaller studies, strengthening the chance of a definitive efficacy readout. This durability improves partner interest, regulatory credibility and strategic optionality regardless of short‑term market moves.
Material Cash Balance Supporting Near-term OperationsA cash position of ~EUR 231m provides multi‑quarter runway to execute NATiV3 and regulatory work without immediate dilution. This buffer supports disciplined trial completion, regulatory interactions and selective commercial readiness investments, reducing near‑term execution risk ahead of a pivotal readout.
Regulatory Designations And Supportive Phase II SignalsBreakthrough/Fast Track status plus positive Phase II efficacy reinforce biological plausibility and speed potential regulatory review. These durable advantages increase odds of expedited interactions, bolster licensing/partnering leverage, and underpin commercial differentiation if Phase III confirms benefits.
Bears Say
Negative Equity And Weakened Balance SheetSustained negative equity signals accumulated losses have overwhelmed capital, constraining borrowing capacity and increasing creditor and counterparty risk. This structural weakness heightens future financing needs and potential dilution, limiting strategic flexibility over the coming quarters.
Persistent Operating Cash Burn With Negative Free Cash FlowConsistent negative operating and free cash flow demonstrates that losses translate into real cash consumption, creating an ongoing need for external capital. Over a multi‑quarter horizon this undermines self‑funding, elevates dilution risk, and can force tradeoffs between R&D, commercial preparation and balance sheet repair.
Safety/tolerability Issues (weight Gain, Fluid Retention) Invite ScrutinyDose‑related weight gain and fluid retention are intrinsic to pan‑PPAR pharmacology and can limit label claims, restrict indicated populations or require risk‑mitigation strategies. Even absent CHF signals, persistent safety issues could reduce commercial uptake, complicate regulatory approvals and require additional studies or labeling constraints.
Inventiva News
0RNK FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest share price was €2.85 and its highest was €6.19 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €897.69M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 48 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Inventiva SA dividends here
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.33.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -7.566%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in GB:0RNK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
0RNK Stock 12 Month Forecast
Average Price Target
€8.68
▲(80.81% Upside)